Not Yet RecruitingPhase 2/3

Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis

China30 participantsStarted 2025-06-01

Plain-language summary

This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.

Who can participate

Age range1 Year – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Fulfillment of at least five of the eight HLH-2004 criteria for HLH;
✓. Age 1-70 years old;
✓. No prior chemotherapy for HLH;
✓. Confirmed not pregnant and willing to use effective contraceptive measures during the study period, with the last dose of medication administered at least 12 months prior;
✓. Signed informed consent prior to study participation.

Exclusion criteria

✕. According to the New York Heart Association (NYHA) score, patients with heart disease of grade II or above (including grade II);
✕. HIV-infected patients;
✕. Patients with severe renal dysfunction (glomerular filtration rate \<15 mL/min);
✕. Patients with severe liver cirrhosis (MELD score\>20);
✕. Uncontrollable infections (including lung infections, intestinal infections, etc.);
✕. Have serious mental illness;
✕. Have a history of active tumor;
✕. Participate in other clinical investigators at the same time;

What they're measuring

60-days OS

Timeframe: 60 days

Trial details

NCT IDNCT06951971

SponsorThe First Affiliated Hospital of Soochow University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06-01

Contact for this trial

Yue Song, Dr

+86 18810253070 xueqifeng1992@163.com

View on ClinicalTrials.gov More Hemophagocytic Lymphohistiocytosis (HLH) trials